TrialInternational journal of clinical oncology2026

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma.

Eiji Kikuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.